Accordingly, cancer cells are likely to exploit the A2AR pathway to promote metastasis and progression, and an increased expression of A2AR not only in the primary tumor but also in metastatic lesions probably has an anti-immune effect that enables cancer cells to survive and develop resistance to anti-tumor agents. This evidence concerns the gene ADORA2A and cancer.